Brought to you by 
Novartis receives option to acquire Elixir
09 Dec 2009
Executive Summary
Concurrent with the closing of its $12mm Series E venture round, Elixir Pharmaceuticals (metabolic diseases) has granted Novartis the exclusive option to buy the company.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Preliminary
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis receives option to acquire Elixir
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice